Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
10709
Millions of yen (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary Materials to the Earnings SummaryFiscal year ending September 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales62,386 Millions of yen+20.7%
Operating profit6,355 Millions of yen+27.4%
Ordinary income6,176 Millions of yen+38.5%
Net income2,831 Millions of yen-5.6%
Gross Profit Margin39 %
Operating profit margin10.2 %
Selling, general and administrative expenses17,966 Millions of yen
Results for the three months of the current quarter
Net Sales
17,004 Millions of yen
Gross Profit Margin
39.1 %
Full-year earnings forecast
Net Sales
59,250 Millions of yen
Gross profit
24,820 Millions of yen
Selling, general and administrative expenses
18,700 Millions of yen
Operating profit
6,120 Millions of yen
Ordinary income
5,880 Millions of yen
Net income
2,240 Millions of yen
EBITDA
10,102 Millions of yen
Capital expenditures
3,470 Millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales105.3
Gross profit98
Selling, general and administrative expenses96.1
Operating profit103.8
Ordinary income105
Net income126.4
EBITDA104.6
Capital expenditures80.2
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Women’s healthcareDetailsGrowth in Femeno® capsules and Alyssa® combination tablets
- BiosimilarsDetailsGrowth in ustekinumab and contribution from aflibercept
- CMODetailsGrowth in overseas CMO operations, specifically OLIC in Thailand
- Decline in gross profit marginDetailsHigher costs of imported products due to foreign exchange movements
- Net income decline2,000 Millions of yenDetailsValuation loss on investment securities
New initiatives
- Obtained marketing authorization for ustekinumab BS intravenous infusion 130 mg “F”
- Obtained marketing authorization for golimumab BS subcutaneous injection 50 mg auto-injector “F”
- Obtained marketing authorization for pomalidomide capsules
- Acquisition of DX Certified Business Operator Certification
Key KPIsA metric the company considers important as a management benchmark.
- Earnings per share (based on operating income after tax)173.15 YenYear on year against the same period last year+22.0%
- ROE (based on operating income after tax)8.9 %Year-on-year change1.4
- EBITDA10,562 Millions of yenYear on year against the same period last year+19.1%
- Capital expenditures2,783 Millions of yenYear on year against the same period last year+16.3%
- Depreciation and amortization (including equipment lease expenses)4,207 Millions of yenYear on year against the same period last year+8.6%
Segment results
Women’s healthcare
Net Sales27,374 Millions of yen
Year on year against the same period last year+22.4%
Biosimilars
Net Sales5,019 Millions of yen
Year on year against the same period last year+154.4%
CMO
Net Sales8,975 Millions of yen
Year on year against the same period last year+7.6%
Other
Net Sales21,016 Millions of yen
Year on year against the same period last year+10.7%
Medium-term management plan targets
Three growth strategies: women's healthcare, biosimilars and global CMO. Numerical targets and target year: Not disclosedCapital expenditures
2,783 Millions of yen
| Item | Details |
|---|---|
| Document type | Supplementary Materials to the Earnings Summary |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Net Sales | 62,386 Millions of yen (YoY +20.7%) |
| Operating profit | 6,355 Millions of yen (YoY +27.4%) |
| Ordinary income | 6,176 Millions of yen (YoY +38.5%) |
| Net income | 2,831 Millions of yen (YoY -5.6%) |
| Gross Profit Margin | 39 % |
| Operating profit margin | 10.2 % |
| Selling, general and administrative expenses | 17,966 Millions of yen |
| Results for the three months of the current quarter | Net Sales 17,004 Millions of yen / Gross Profit Margin 39.1 % |
| Full-year earnings forecast | Net Sales 59,250 Millions of yen / Gross profit 24,820 Millions of yen / Selling, general and administrative expenses 18,700 Millions of yen / Operating profit 6,120 Millions of yen / Ordinary income 5,880 Millions of yen / Net income 2,240 Millions of yen / EBITDA 10,102 Millions of yen / Capital expenditures 3,470 Millions of yen |
| Progress against full-year forecast | Net Sales 105.3 / Gross profit 98 / Selling, general and administrative expenses 96.1 / Operating profit 103.8 / Ordinary income 105 / Net income 126.4 / EBITDA 104.6 / Capital expenditures 80.2 |
| Segment results | Women’s healthcare Net Sales 27,374 Millions of yen / yoy_pct 22.4 Millions of yen / Biosimilars Net Sales 5,019 Millions of yen / yoy_pct 154.4 Millions of yen / CMO Net Sales 8,975 Millions of yen / yoy_pct 7.6 Millions of yen / Other Net Sales 21,016 Millions of yen / yoy_pct 10.7 Millions of yen |
| Breakdown of Factors Affecting the Change | Item Women’s healthcare / Details Growth in Femeno® capsules and Alyssa® combination tablets, Item Biosimilars / Details Growth in ustekinumab and contribution from aflibercept, Item CMO / Details Growth in overseas CMO operations, specifically OLIC in Thailand, Item Decline in gross profit margin / Details Higher costs of imported products due to foreign exchange movements, Item Net income decline / Amount 2,000 Millions of yen / Details Valuation loss on investment securities |
| Key KPIs | Indicator name Earnings per share (based on operating income after tax) / Value 173.15 Yen / Year on year against the same period last year 22 Yen, Indicator name ROE (based on operating income after tax) / Value 8.9 % / Year-on-year change 1.4 %, Indicator name EBITDA / Value 10,562 Millions of yen / Year on year against the same period last year 19.1 Millions of yen, Indicator name Capital expenditures / Value 2,783 Millions of yen / Year on year against the same period last year 16.3 Millions of yen, Indicator name Depreciation and amortization (including equipment lease expenses) / Value 4,207 Millions of yen / Year on year against the same period last year 8.6 Millions of yen |
| Medium-term management plan targets | Three growth strategies: women's healthcare, biosimilars and global CMO. Numerical targets and target year: Not disclosed |
| Capital expenditures | 2,783 Millions of yen |
| New initiatives | Obtained marketing authorization for ustekinumab BS intravenous infusion 130 mg “F”, Obtained marketing authorization for golimumab BS subcutaneous injection 50 mg auto-injector “F”, Obtained marketing authorization for pomalidomide capsules, Acquisition of DX Certified Business Operator Certification |
Items this document does not state (13)
Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In women's healthcare, Femeno® capsules and Alyssa® combination tablets drove sales growth; in biosimilars, ustekinumab and aflibercept contributed; and in CMO, overseas CMO operations, specifically OLIC in Thailand, drove growth. Growth in high-gross-margin products and licensing income contributed to gross profit, while the gross profit margin declined due to higher costs of imported products resulting from foreign exchange movements. Net income was affected by a ¥2,000 million valuation loss on investment securities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.